FDMT

4D Molecular Therapeutics, Inc. [FDMT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

FDMT Stock Summary

Top 10 Correlated ETFs

FDMT


Top 10 Correlated Stocks

FDMT


In the News

07:06 04 Mar 2024 FDMT

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.84 per share a year ago.

02:50 04 Mar 2024 FDMT

Why Is 4D Molecular (FDMT) Stock Up 85% Today?

Some massive winners in the world of biotech companies continue to emerge today. 4D Molecular Therapeutics (NASDAQ: FDMT ) is the latest company to generate massive attention from investors, with FDMT stock rocketing over 80% higher in early afternoon trading.

12:41 04 Mar 2024 FDMT

4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'

Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy.

08:00 04 Mar 2024 FDMT

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

EMERYVILLE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that it will host a live webcast to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM clinical trial in wet AMD patients with severe disease activity and high treatment burden, as well as provide a program update on Monday, February 5 at 8:00 a.m. ET. Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, will also present in the webcast and be available for Q&A.

01:01 04 Mar 2024 FDMT

All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy

4D Molecular Therapeutics, Inc. (FDMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

08:00 04 Mar 2024 FDMT

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

EMERYVILLE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that the initial interim landmark data analysis (24 weeks) from the randomized Dose Expansion stage (N=50) of the Phase 2 PRISM clinical trial in high anti-VEGF (vascular endothelial growth factor) treatment need (6-12 anti-VEGF injections in prior 12 months) wet AMD patients will be presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference being held virtually on February 3, 2024.

08:00 04 Mar 2024 FDMT

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, announced today that management will participate in a fireside chat at an upcoming investor conference in November. Members of the management team will also be available for one-on-one meetings in connection with this meeting.

08:00 04 Mar 2024 FDMT

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC

EMERYVILLE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) --  4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) and that it will host a live webcast to discuss the data in detail and provide a program update on Wednesday, November 1, 2023 at 4:30 p.m. ET.

12:19 04 Mar 2024 FDMT

4D Molecular Therapeutics: Some Failures, A Few Key Successes

4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions in patients. The company has five product candidates in clinical trials, targeting ophthalmology, cardiology, and pulmonology. The cystic fibrosis program with 4D-710 showed success, with improvements in lung function and quality of life, providing a potential breathing space for patients ineligible for other treatments.

04:05 04 Mar 2024 FDMT

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today that management will present company overviews and participate in fireside chats at upcoming investor conferences in September and October. Members of the management team will also be available for one-on-one meetings in connection with these meetings.

FDMT Financial details

Company Rating
Neutral
Market Cap
1.45B
Income
-94.4M
Revenue
21.99M
Book val./share
7.81
Cash/share
7.56
Dividend
-
Dividend %
-
Employees
144
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-8.72
Forward P/E
-9.21
PEG
6.18
P/S
37.9
P/B
2.5
P/C
3.88
P/FCF
-10.87
Quick Ratio
17.6
Current Ratio
18.07
Debt / Equity
0.05
LT Debt / Equity
0.04
-
-
EPS (TTM)
-2.68
EPS next Y
-3.19
EPS next Q
1.58
EPS this Y
-99.92%
EPS next Y
19.03%
EPS next 5Y
19.03%
EPS last 5Y
-76.42%
Revenue last 5Y
-100%
Revenue Q/Q
8353.56%
EPS Q/Q
-68.83%
-
-
-
-
SMA20
54.36%
SMA50
70.26%
SMA100
127.34%
Inst Own
83.17%
Inst Trans
0.66%
ROA
-26%
ROE
244%
ROC
-0.31%
Gross Margin
100%
Oper. Margin
-477%
Profit Margin
-429%
Payout
-
Shs Outstand
49.34M
Shs Float
42.26M
-
-
-
-
Target Price
44
52W Range
9.44-35.613
52W High
-16.09%
52W Low
+226.33%
RSI
61.39
Rel Volume
0.46
Avg Volume
1.07M
Volume
493.69K
Perf Week
10.91%
Perf Month
72.26%
Perf Quarter
87.43%
Perf Half Y
75.76%
-
-
-
-
Beta
2.619
-
-
Volatility
1.2%, 5.2%
Prev Close
4.82%
Price
29.37
Change
2.51%

FDMT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.130.472.120.650.1
Net income per share
-0.76-3.57-8.79-2.46-3.12
Operating cash flow per share
-1.3-2.47-7.92-2.49-2.68
Free cash flow per share
-1.33-2.69-8.07-2.82-3.04
Cash per share
7.333.3543.0314.7911.74
Book value per share
-2.2-4.9239.87-7.46-9.72
Tangible book value per share
-2.2-4.9239.87-7.467.15
Share holders equity per share
-2.2-4.9239.87-7.46-9.72
Interest debt per share
0.01000.590.3
Market cap
506.99M600.83M266.55M608.41M718.52M
Enterprise value
415.23M551.18M-10.18M309.42M516M
P/E ratio
-53.08-11.35-4.71-8.91-7.11
Price to sales ratio
35.8886.0119.5833.73229.63
POCF ratio
-31.2-16.37-5.24-8.8-8.29
PFCF ratio
-30.42-15.05-5.13-7.78-7.32
P/B Ratio
-18.38-8.231.04-2.94-2.28
PTB ratio
-18.38-8.231.04-2.94-2.28
EV to sales
29.3978.9-0.7517.15164.91
Enterprise value over EBITDA
-42.8-13.960.18-4.34-4.69
EV to operating cash flow
-25.55-15.010.2-4.48-5.95
EV to free cash flow
-24.91-13.810.2-3.95-5.25
Earnings yield
-0.02-0.09-0.21-0.11-0.14
Free cash flow yield
-0.03-0.07-0.19-0.13-0.14
Debt to equity
000-0.08-0.05
Debt to assets
0000.050.06
Net debt to EBITDA
9.461.265.014.191.84
Current ratio
11.684.0516.8819.3114.02
Interest coverage
000017.14
Income quality
1.70.740.90.970.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.441.991.271.5510.52
Research and developement to revenue
1.35.543.93.425.65
Intangibles to total assets
00000
Capex to operating cash flow
0.030.090.020.130.13
Capex to revenue
-0.03-0.46-0.07-0.51-3.69
Capex to depreciation
-0.59-3.19-0.69-3.02-2.97
Stock based compensation to revenue
0.10.510.370.765.47
Graham number
6.1519.8788.8120.3426.14
ROIC
0.410.75-0.220.390.37
Return on tangible assets
-0.1-0.91-0.2-0.19-0.39
Graham Net
-2.55-5.4538.24-5.5710.73
Working capital
86.01M39.55M265.91M299.09M204.78M
Tangible asset value
-27.59M-72.97M256.39M-207M231.34M
Net current asset value
-30.49M-78.7M250.71M-245.05M190M
Invested capital
000-0.08-0.05
Average receivables
722.5K1.05M1.23M766.5K373.5K
Average payables
707K1.35M1.77M3.28M4.04M
Average inventory
000-4.25M-7.15M
Days sales outstanding
29.0351.139.850.9581.66
Days payables outstanding
016.4412.3575.78312.51
Days of inventory on hand
000-1.03K-544.49
Receivables turnover
12.577.149.16383.794.47
Payables turnover
022.229.680.631.17
Inventory turnover
000-0.36-0.67
ROE
0.350.73-0.220.330.32
Capex per share
-0.03-0.22-0.16-0.33-0.36

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.020.040.010.010.48
Net income per share
-0.74-0.84-0.83-0.77-0.24
Operating cash flow per share
-0.65-0.69-0.85-0.58-0.03
Free cash flow per share
-0.71-0.72-0.88-0.6-0.04
Cash per share
7.036.69.8910.037.56
Book value per share
7.767.15-10.49-9.727.81
Tangible book value per share
7.767.156.68-9.727.81
Share holders equity per share
7.767.15-10.49-9.727.81
Interest debt per share
0.540.460.440.410.36
Market cap
260.38M718.52M562.52M692.72M537.93M
Enterprise value
168.64M682.29M376.34M398M277.41M
P/E ratio
-2.7-6.59-5.16-5.85-13.11
Price to sales ratio
520.76576.21.89K2.9K26.62
POCF ratio
-12.39-32.35-20.16-31.39-459.37
PFCF ratio
-11.33-30.83-19.45-30.29-341.32
P/B Ratio
1.043.11-1.64-1.861.63
PTB ratio
1.043.11-1.64-1.861.63
EV to sales
337.27547.151.26K1.67K13.73
Enterprise value over EBITDA
-6.58-24.96-12.5-12.39-22.05
EV to operating cash flow
-8.02-30.71-13.49-18.04-236.9
EV to free cash flow
-7.34-29.27-13.01-17.4-176.02
Earnings yield
-0.09-0.04-0.05-0.04-0.02
Free cash flow yield
-0.09-0.03-0.05-0.030
Debt to equity
0.070.07-0.05-0.040.05
Debt to assets
0.060.060.060.040.04
Net debt to EBITDA
3.581.336.189.1720.71
Current ratio
17.1414.0218.3622.5718.07
Interest coverage
-33.3323.2621.3200
Income quality
0.820.810.970.750.11
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
16.116.7926.8236.780.45
Research and developement to revenue
37.8817.2475.2198.681.24
Intangibles to total assets
00000
Capex to operating cash flow
0.090.050.040.040.35
Capex to revenue
-3.93-0.88-3.4-3.37-0.02
Capex to depreciation
-2.23-0.79-0.72-0.56-0.29
Stock based compensation to revenue
9.043.4914.1620.790.23
Graham number
11.411.6514.02136.53
ROIC
-0.09-0.110.090.09-0.02
Return on tangible assets
-0.09-0.1-0.11-0.08-0.03
Graham Net
6.145.669.12-8.896.82
Working capital
218.91M204.78M195.76M296.59M310.08M
Tangible asset value
251.44M231.34M218.61M-372.79M329.93M
Net current asset value
203.76M190M181.63M-414.95M296.56M
Invested capital
0.070.07-0.05-0.040.05
Average receivables
0350K350K00
Average payables
2.4M2.4M2.87M2.95M4.1M
Average inventory
0-350K-350K00
Days sales outstanding
050.52000
Days payables outstanding
151.54215.4153.48220.15303.85
Days of inventory on hand
0-45.39000
Receivables turnover
01.78000
Payables turnover
0.590.420.590.410.3
Inventory turnover
0-1.98000
ROE
-0.1-0.120.080.08-0.03
Capex per share
-0.06-0.03-0.03-0.02-0.01

FDMT Frequently Asked Questions

What is 4D Molecular Therapeutics, Inc. stock symbol ?

4D Molecular Therapeutics, Inc. is a US stock , located in Emeryville of Ca and trading under the symbol FDMT

Is 4D Molecular Therapeutics, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $44. The lowest prediction is $30 and the highest is $70

What is FDMT stock prediction ?

With a median analyst target price of $70, 1 stock analysts have made 1 forecasts in last 90 days. $70 is the lowest and $70 is the greatest projection.

What is 4D Molecular Therapeutics, Inc. stock quote today ?

4D Molecular Therapeutics, Inc. stock price is $29.37 today.

Is 4D Molecular Therapeutics, Inc. stock public?

Yes, 4D Molecular Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks